| Annual · values | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -33.95 M USD | -33.41 M USD | -43.94 M USD | -57.21 M USD | -43.06 M USD | -52.63 M USD |
| Depreciation & Amortization | 35174 USD | 153301 USD | 207145 USD | 264600 USD | 270754 USD | 279234 USD |
| Stock-Based Compensation | — | — | — | — | — | — |
| Capital Expenditures | 20028 USD | -21394 USD | -84191 USD | -14943 USD | -68507 USD | -144928 USD |
| Cash Flow from Investing | — | — | — | — | — | — |
| Cash Flow from Financing | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -31.11 M USD | -34.90 M USD | -46.54 M USD | -57.50 M USD | -39.31 M USD | -52.13 M USD |
Crescent Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies in the pharmaceutical sector. It specializes in advancing treatments that address significant unmet medical needs, often targeting niche or rare diseases. The company’s pipeline and research efforts aim to bring novel drug candidates through clinical development stages to improve patient outcomes. Crescent Biopharma plays a role in the broader healthcare and life sciences industry by contributing to medical innovation and therapeutic advancements. Its presence in financial markets, including listing on the Frankfurt Stock Exchange, allows investors to track its progress and financial performance as it works toward enhancing treatment options in biomedicine.